What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

View Full Paper

Ask AI

Bookmark

Authors

Subgroup analysis shows disease burden comparisons between blood and bone marrow in transplant patients, indicating MRD status importance.

MRD negativity was achieved in 82% of PB samples and 31% of BM samples after therapy, highlighting the significance of sample selection.
At baseline, all samples tested MRD positive, with a median disease burden of 41,400 sequences/million cells in BM samples.
Next-generation sequencing was utilized to assess disease burden differences across bone marrow and peripheral blood over multiple timepoints.
These findings suggest caution in using PB negativity as a surrogate for MRD status in newly diagnosed multiple myeloma.

Diamond et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Subgroup analysis shows disease burden comparisons between blood and bone marrow in transplant patients, indicating MRD status importance.

MRD negativity was achieved in 82% of PB samples and 31% of BM samples after therapy, highlighting the significance of sample selection.
At baseline, all samples tested MRD positive, with a median disease burden of 41,400 sequences/million cells in BM samples.
Next-generation sequencing was utilized to assess disease burden differences across bone marrow and peripheral blood over multiple timepoints.
These findings suggest caution in using PB negativity as a surrogate for MRD status in newly diagnosed multiple myeloma.

Diamond et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark